Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

OBJECTIVES: Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatmen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ Open
Hauptverfasser: Dane, Faysal, Ozgurdal, Kirhan, Yalçın, Şuayib, Benekli, Mustafa, Aykan, Nuri Faruk, Yücel, İdris, Özkan, Metin, Evrensel, Turkkan, Sevinç, Alper, Coskun, Hasan Şenol, Sanli, Ulus Ali, Kara, Ismail Oguz, Yumuk, Perran Fulden
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2020
Schlagworte:
Oncology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170555/
https://ncbi.nlm.nih.gov/pubmed/32220908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-027665
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge